메뉴 건너뛰기




Volumn 17, Issue 2, 2017, Pages 79-92

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; TRANSCRIPTOME;

EID: 85008339326     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.126     Document Type: Review
Times cited : (636)

References (159)
  • 1
    • 84875804295 scopus 로고    scopus 로고
    • Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
    • Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49, 1374-1403 (2013).
    • (2013) Eur. J. Cancer , vol.49 , pp. 1374-1403
    • Ferlay, J.1
  • 3
    • 84964977079 scopus 로고    scopus 로고
    • Colorectal cancer on the decline - Why screening can't explain it all
    • Welch, H. G. & Robertson, D. J. Colorectal cancer on the decline - why screening can't explain it all. N. Engl. J. Med. 374, 1605-1607 (2016).
    • (2016) N. Engl. J. Med. , vol.374 , pp. 1605-1607
    • Welch, H.G.1    Robertson, D.J.2
  • 4
    • 84942295564 scopus 로고    scopus 로고
    • First-line chemotherapy for mCRC - A review and evidence-based algorithm
    • Cremolini, C. et al. First-line chemotherapy for mCRC - a review and evidence-based algorithm. Nat. Rev. Clin. Oncol. 12, 607-619 (2015).
    • (2015) Nat. Rev. Clin. Oncol. , vol.12 , pp. 607-619
    • Cremolini, C.1
  • 5
    • 84965190416 scopus 로고    scopus 로고
    • Overcoming resistance to anti-EGFR therapy in colorectal cancer
    • Dienstmann, R., Salazar, R. & Tabernero, J. Overcoming resistance to anti-EGFR therapy in colorectal cancer. Am. Soc. Clin. Oncol. Educ. Book https://dx.doi.org/10.14694/EdBook-AM.2015.35. e149 (2015).
    • (2015) Am. Soc. Clin. Oncol. Educ. Book
    • Dienstmann, R.1    Salazar, R.2    Tabernero, J.3
  • 6
    • 79751489596 scopus 로고    scopus 로고
    • Molecular genetics of colorectal cancer
    • Fearon, E. R. Molecular genetics of colorectal cancer. Ann. Rev. Pathol. 6, 479-507 (2011).
    • (2011) Ann. Rev. Pathol. , vol.6 , pp. 479-507
    • Fearon, E.R.1
  • 7
    • 0025312728 scopus 로고
    • A genetic model for colorectal tumorigenesis
    • Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
    • (1990) Cell , vol.61 , pp. 759-767
    • Fearon, E.R.1    Vogelstein, B.2
  • 8
    • 84875490185 scopus 로고    scopus 로고
    • Cancer genome landscapes
    • Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
    • (2013) Science , vol.339 , pp. 1546-1558
    • Vogelstein, B.1
  • 9
    • 0023748414 scopus 로고
    • Genetic alterations during colorectal-tumor development
    • Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525-532 (1988).
    • (1988) N. Engl. J. Med. , vol.319 , pp. 525-532
    • Vogelstein, B.1
  • 10
    • 33749993417 scopus 로고    scopus 로고
    • The consensus coding sequences of human breast and colorectal cancers
    • Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006).
    • (2006) Science , vol.314 , pp. 268-274
    • Sjoblom, T.1
  • 11
    • 84863922124 scopus 로고    scopus 로고
    • Comprehensive molecular characterization of human colon and rectal cancer
    • Cancer Genome Atlas Network
    • Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
    • (2012) Nature , vol.487 , pp. 330-337
  • 12
    • 84865459654 scopus 로고    scopus 로고
    • Recurrent R-spondin fusions in colon cancer
    • Seshagiri, S. et al. Recurrent R-spondin fusions in colon cancer. Nature 488, 660-664 (2012).
    • (2012) Nature , vol.488 , pp. 660-664
    • Seshagiri, S.1
  • 13
    • 84924422753 scopus 로고    scopus 로고
    • Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids
    • Matano, M. et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat. Med. 21, 256-262 (2015).
    • (2015) Nat. Med. , vol.21 , pp. 256-262
    • Matano, M.1
  • 14
    • 77951627056 scopus 로고    scopus 로고
    • The chromosomal instability pathway in colon cancer
    • Pino, M. S. & Chung, D. C. The chromosomal instability pathway in colon cancer. Gastroenterology 138, 2059-2072 (2010).
    • (2010) Gastroenterology , vol.138 , pp. 2059-2072
    • Pino, M.S.1    Chung, D.C.2
  • 15
    • 84877595332 scopus 로고    scopus 로고
    • Molecular dissection of microsatellite instable colorectal cancer
    • Vilar, E. & Tabernero, J. Molecular dissection of microsatellite instable colorectal cancer. Cancer Discov. 3, 502-511 (2013).
    • (2013) Cancer Discov. , vol.3 , pp. 502-511
    • Vilar, E.1    Tabernero, J.2
  • 16
    • 84866091151 scopus 로고    scopus 로고
    • Serrated lesions of the colorectum: Review and recommendations from an expert panel
    • Rex, D. K. et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am. J. Gastroenterol. 107, 1315-1329 (2012).
    • (2012) Am. J. Gastroenterol. , vol.107 , pp. 1315-1329
    • Rex, D.K.1
  • 17
    • 84927577882 scopus 로고    scopus 로고
    • RNF43 is frequently mutated in colorectal and endometrial cancers
    • Giannakis, M. et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat. Genet. 46, 1264-1266 (2014).
    • (2014) Nat. Genet. , vol.46 , pp. 1264-1266
    • Giannakis, M.1
  • 18
    • 84952637567 scopus 로고    scopus 로고
    • Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
    • Amatu, A. et al. Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. Br. J. Cancer. 113, 1730-1734 (2015).
    • (2015) Br. J. Cancer. , vol.113 , pp. 1730-1734
    • Amatu, A.1
  • 19
    • 84945152069 scopus 로고    scopus 로고
    • Identification and characterization of RET fusions in advanced colorectal cancer
    • Le Rolle, A. F. et al. Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget 6, 28929-28937 (2015).
    • (2015) Oncotarget , vol.6 , pp. 28929-28937
    • Le Rolle, A.F.1
  • 21
    • 84885184379 scopus 로고    scopus 로고
    • Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer
    • Budinska, E. et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J. Pathol. 231, 63-76 (2013).
    • (2013) J. Pathol. , vol.231 , pp. 63-76
    • Budinska, E.1
  • 22
    • 84877600884 scopus 로고    scopus 로고
    • Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions
    • De Sousa E Melo, F. et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat. Med. 19, 614-618 (2013).
    • (2013) Nat. Med. , vol.19 , pp. 614-618
    • De Sousa, E.1    Melo, F.2
  • 23
    • 84878302099 scopus 로고    scopus 로고
    • Gene expression classification of colon cancer into molecular subtypes: Characterization, validation, and prognostic value
    • Marisa, L. et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 10, e1001453 (2013).
    • (2013) PLoS Med. , vol.10 , pp. e1001453
    • Marisa, L.1
  • 24
    • 84873704094 scopus 로고    scopus 로고
    • Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior
    • Perez-Villamil, B. et al. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer 12, 260 (2012).
    • (2012) BMC Cancer , vol.12 , pp. 260
    • Perez-Villamil, B.1
  • 25
    • 84887989710 scopus 로고    scopus 로고
    • Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition
    • Roepman, P. et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int. J. Cancer 134, 552-562 (2014).
    • (2014) Int. J. Cancer , vol.134 , pp. 552-562
    • Roepman, P.1
  • 26
    • 84877619075 scopus 로고    scopus 로고
    • A colorectal cancer classification system that associates cellular phenotype and responses to therapy
    • Sadanandam, A. et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 19, 619-625 (2013).
    • (2013) Nat. Med. , vol.19 , pp. 619-625
    • Sadanandam, A.1
  • 27
    • 84871676568 scopus 로고    scopus 로고
    • Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines
    • Schlicker, A. et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med. Genomics 5, 66 (2012).
    • (2012) BMC Med. Genomics , vol.5 , pp. 66
    • Schlicker, A.1
  • 28
    • 84946571753 scopus 로고    scopus 로고
    • The consensus molecular subtypes of colorectal cancer
    • Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350-1356 (2015).
    • (2015) Nat. Med. , vol.21 , pp. 1350-1356
    • Guinney, J.1
  • 29
    • 84925701525 scopus 로고    scopus 로고
    • Stromal contribution to the colorectal cancer transcriptome
    • Isella, C. et al. Stromal contribution to the colorectal cancer transcriptome. Nat. Genet. 47, 312-319 (2015).
    • (2015) Nat. Genet. , vol.47 , pp. 312-319
    • Isella, C.1
  • 30
    • 84982141292 scopus 로고    scopus 로고
    • Challenging the cancer molecular stratification dogma: Intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer
    • Dunne, P. D. et al. Challenging the cancer molecular stratification dogma: intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer. Clin. Cancer Res. 22, 4095-4104 (2016).
    • (2016) Clin. Cancer Res. , vol.22 , pp. 4095-4104
    • Dunne, P.D.1
  • 31
    • 70349331678 scopus 로고    scopus 로고
    • Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells
    • Yun, J. et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325, 1555-1559 (2009).
    • (2009) Science , vol.325 , pp. 1555-1559
    • Yun, J.1
  • 32
    • 84875894714 scopus 로고    scopus 로고
    • Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
    • Son, J. et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101-105 (2013).
    • (2013) Nature , vol.496 , pp. 101-105
    • Son, J.1
  • 33
    • 84860321700 scopus 로고    scopus 로고
    • Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
    • Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656-670 (2012).
    • (2012) Cell , vol.149 , pp. 656-670
    • Ying, H.1
  • 34
    • 84905009543 scopus 로고    scopus 로고
    • Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
    • Brunelli, L., Caiola, E., Marabese, M., Broggini, M. & Pastorelli, R. Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells. Oncotarget 5, 4722-4731 (2014).
    • (2014) Oncotarget , vol.5 , pp. 4722-4731
    • Brunelli, L.1    Caiola, E.2    Marabese, M.3    Broggini, M.4    Pastorelli, R.5
  • 35
    • 84878464291 scopus 로고    scopus 로고
    • Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids
    • Kamphorst, J. J. et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc. Natl Acad. Sci. USA 110, 8882-8887 (2013).
    • (2013) Proc. Natl Acad. Sci. USA , vol.110 , pp. 8882-8887
    • Kamphorst, J.J.1
  • 36
    • 84960154307 scopus 로고    scopus 로고
    • Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities
    • Kerr, E. M., Gaude, E., Turrell, F. K., Frezza, C. & Martins, C. P. Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities. Nature 531, 110-113 (2016).
    • (2016) Nature , vol.531 , pp. 110-113
    • Kerr, E.M.1    Gaude, E.2    Turrell, F.K.3    Frezza, C.4    Martins, C.P.5
  • 37
    • 84872600554 scopus 로고    scopus 로고
    • Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties
    • Schwitalla, S. et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152, 25-38 (2013).
    • (2013) Cell , vol.152 , pp. 25-38
    • Schwitalla, S.1
  • 38
    • 84977616813 scopus 로고    scopus 로고
    • TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype
    • Fessler, E. et al. TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. EMBO Mol. Med. 8, 745-760 (2016).
    • (2016) EMBO Mol. Med. , vol.8 , pp. 745-760
    • Fessler, E.1
  • 39
    • 79951815749 scopus 로고    scopus 로고
    • Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer
    • Tosolini, M. et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res. 71, 1263-1271 (2011).
    • (2011) Cancer Res. , vol.71 , pp. 1263-1271
    • Tosolini, M.1
  • 40
    • 33749319703 scopus 로고    scopus 로고
    • Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
    • Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
    • (2006) Science , vol.313 , pp. 1960-1964
    • Galon, J.1
  • 41
    • 84885724091 scopus 로고    scopus 로고
    • Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer
    • Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782-795 (2013).
    • (2013) Immunity , vol.39 , pp. 782-795
    • Bindea, G.1
  • 42
    • 84866852663 scopus 로고    scopus 로고
    • Cancer classification using the Immunoscore: A worldwide task force
    • Galon, J. et al. Cancer classification using the Immunoscore: a worldwide task force. J. Transl Med. 10, 205 (2012).
    • (2012) J. Transl Med. , vol.10 , pp. 205
    • Galon, J.1
  • 43
    • 84980489465 scopus 로고    scopus 로고
    • Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1, 336 patients
    • abstr. 3500
    • Galon, J. et al. Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: results of a worldwide consortium-based analysis of 1, 336 patients. J. Clin. Oncol. 34, abstr. 3500 (2016).
    • (2016) J. Clin. Oncol. , vol.34
    • Galon, J.1
  • 44
    • 84964311408 scopus 로고    scopus 로고
    • Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
    • Saito, T. et al. Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat. Med. 22, 679-684 (2016).
    • (2016) Nat. Med. , vol.22 , pp. 679-684
    • Saito, T.1
  • 45
    • 84922369377 scopus 로고    scopus 로고
    • The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints
    • Llosa, N. J. et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 5, 43-51 (2015).
    • (2015) Cancer Discov. , vol.5 , pp. 43-51
    • Llosa, N.J.1
  • 46
    • 84931426001 scopus 로고    scopus 로고
    • Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy
    • Angelova, M. et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 16, 64 (2015).
    • (2015) Genome Biol. , vol.16 , pp. 64
    • Angelova, M.1
  • 47
    • 84982161471 scopus 로고    scopus 로고
    • Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy
    • Becht, E. et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin. Cancer Res. 22, 4057-4066 (2016).
    • (2016) Clin. Cancer Res. , vol.22 , pp. 4057-4066
    • Becht, E.1
  • 48
    • 84919385463 scopus 로고    scopus 로고
    • Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type
    • Gatalica, Z. et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol. Biomarkers Prev. 23, 2965-2970 (2014).
    • (2014) Cancer Epidemiol. Biomarkers Prev. , vol.23 , pp. 2965-2970
    • Gatalica, Z.1
  • 49
    • 84942922149 scopus 로고    scopus 로고
    • Correlation between density of CD8+ T-cell infiltrate in microsatellite unstable colorectal cancers and frameshift mutations: A rationale for personalized immunotherapy
    • Maby, P. et al. Correlation between density of CD8+ T-cell infiltrate in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy. Cancer Res. 75, 3446-3455 (2015).
    • (2015) Cancer Res. , vol.75 , pp. 3446-3455
    • Maby, P.1
  • 50
    • 84937519151 scopus 로고    scopus 로고
    • CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function
    • Chun, E. et al. CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep. 12, 244-257 (2015).
    • (2015) Cell Rep. , vol.12 , pp. 244-257
    • Chun, E.1
  • 51
    • 84868613705 scopus 로고    scopus 로고
    • Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
    • Grivennikov, S. I. et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491, 254-258 (2012).
    • (2012) Nature , vol.491 , pp. 254-258
    • Grivennikov, S.I.1
  • 52
    • 84959422566 scopus 로고    scopus 로고
    • The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis
    • Mlecnik, B. et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci. Transl Med. 8, 327ra26 (2016).
    • (2016) Sci. Transl Med. , vol.8 , pp. 327ra26
    • Mlecnik, B.1
  • 53
    • 84918816499 scopus 로고    scopus 로고
    • Ulcerative colitis-associated colorectal cancer
    • Yashiro, M. Ulcerative colitis-associated colorectal cancer. World J. Gastroenterol. 20, 16389-16397 (2014).
    • (2014) World J. Gastroenterol. , vol.20 , pp. 16389-16397
    • Yashiro, M.1
  • 54
    • 85010889847 scopus 로고    scopus 로고
    • Correlation of WNT/β-catenin pathway activation with immune exclusion across most human cancers
    • abstr. 3004
    • Luke, J. J. Correlation of WNT/β-catenin pathway activation with immune exclusion across most human cancers. J. Clin. Oncol. 34, abstr. 3004 (2016).
    • (2016) J. Clin. Oncol. , vol.34
    • Luke, J.J.1
  • 55
    • 85010890698 scopus 로고    scopus 로고
    • Immunologic profiling of consensus molecular subtype stratified colorectal cancer primary and liver metastectomy specimens: Implications for immune targeting of proficient mismatch repair CRC
    • abstr. 3520
    • Reilley, M. et al. Immunologic profiling of consensus molecular subtype stratified colorectal cancer primary and liver metastectomy specimens: implications for immune targeting of proficient mismatch repair CRC. J. Clin. Oncol. 34, abstr. 3520 (2016).
    • (2016) J. Clin. Oncol. , vol.34
    • Reilley, M.1
  • 56
    • 84920285505 scopus 로고    scopus 로고
    • Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions
    • Brannon, A. R. et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol. 15, 454 (2014).
    • (2014) Genome Biol. , vol.15 , pp. 454
    • Brannon, A.R.1
  • 57
    • 84907027880 scopus 로고    scopus 로고
    • Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC)
    • abstr. 3509
    • Kopetz, S. et al. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). J. Clin. Oncol. 32, abstr. 3509 (2014).
    • (2014) J. Clin. Oncol. , vol.32
    • Kopetz, S.1
  • 58
    • 84932606172 scopus 로고    scopus 로고
    • Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer
    • Arena, S. et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin. Cancer Res. 21, 2157-2166 (2015).
    • (2015) Clin. Cancer Res. , vol.21 , pp. 2157-2166
    • Arena, S.1
  • 59
    • 84896371874 scopus 로고    scopus 로고
    • Detection of circulating tumor DNA in early- and late-stage human malignancies
    • Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl Med. 6, 224ra24 (2014).
    • (2014) Sci. Transl Med. , vol.6 , pp. 224ra24
    • Bettegowda, C.1
  • 60
    • 84862999938 scopus 로고    scopus 로고
    • Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
    • Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536 (2012).
    • (2012) Nature , vol.486 , pp. 532-536
    • Misale, S.1
  • 61
    • 84926431987 scopus 로고    scopus 로고
    • Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
    • Morelli, M. P. et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann. Oncol. 26, 731-736 (2015).
    • (2015) Ann. Oncol. , vol.26 , pp. 731-736
    • Morelli, M.P.1
  • 62
    • 84936748494 scopus 로고    scopus 로고
    • Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
    • Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795-801 (2015).
    • (2015) Nat. Med. , vol.21 , pp. 795-801
    • Siravegna, G.1
  • 63
    • 84957063275 scopus 로고    scopus 로고
    • Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer
    • Russo, M. et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov. 6, 147-153 (2016).
    • (2016) Cancer Discov. , vol.6 , pp. 147-153
    • Russo, M.1
  • 64
    • 84897389811 scopus 로고    scopus 로고
    • Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing
    • Mohan, S. et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet. 10, e1004271 (2014).
    • (2014) PLoS Genet. , vol.10 , pp. e1004271
    • Mohan, S.1
  • 65
    • 84951766343 scopus 로고    scopus 로고
    • Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) versus cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC)
    • abstr. 740
    • Price, T. J. et al. Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: panitumumab (pmab) versus cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). J. Clin. Oncol. 33, abstr. 740 (2015).
    • (2015) J. Clin. Oncol. , vol.33
    • Price, T.J.1
  • 66
    • 84944079826 scopus 로고    scopus 로고
    • The genomic landscape of response to EGFR blockade in colorectal cancer
    • Bertotti, A. et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 526, 263-267 (2015).
    • (2015) Nature , vol.526 , pp. 263-267
    • Bertotti, A.1
  • 67
    • 84891808183 scopus 로고    scopus 로고
    • The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies
    • Esposito, C. et al. The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biol. Ther. 14, 1143-1146 (2013).
    • (2013) Cancer Biol. Ther. , vol.14 , pp. 1143-1146
    • Esposito, C.1
  • 68
    • 84919608195 scopus 로고    scopus 로고
    • Integrative genomic and transcriptomic characterization of matched primary and metastatic liver and colorectal carcinoma
    • Roessler, S. et al. Integrative genomic and transcriptomic characterization of matched primary and metastatic liver and colorectal carcinoma. Int. J. Biol. Sci. 11, 88-98 (2015).
    • (2015) Int. J. Biol. Sci. , vol.11 , pp. 88-98
    • Roessler, S.1
  • 69
    • 77956107307 scopus 로고    scopus 로고
    • Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain
    • Stange, D. E. et al. Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain. Gut 59, 1236-1244 (2010).
    • (2010) Gut , vol.59 , pp. 1236-1244
    • Stange, D.E.1
  • 70
    • 84884479395 scopus 로고    scopus 로고
    • Expression of HGF and Met in human tissues of colorectal cancers: Biological and clinical implications for synchronous liver metastasis
    • Sun, Y. L. et al. Expression of HGF and Met in human tissues of colorectal cancers: biological and clinical implications for synchronous liver metastasis. Int. J. Med. Sci. 10, 548-559 (2013).
    • (2013) Int. J. Med. Sci. , vol.10 , pp. 548-559
    • Sun, Y.L.1
  • 71
    • 84859428938 scopus 로고    scopus 로고
    • Unique genetic profile of sporadic colorectal cancer liver metastasis versus primary tumors as defined by high-density single-nucleotide polymorphism arrays
    • Munoz-Bellvis, L. et al. Unique genetic profile of sporadic colorectal cancer liver metastasis versus primary tumors as defined by high-density single-nucleotide polymorphism arrays. Mod. Pathol. 25, 590-601 (2012).
    • (2012) Mod. Pathol. , vol.25 , pp. 590-601
    • Munoz-Bellvis, L.1
  • 72
    • 84862772839 scopus 로고    scopus 로고
    • A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
    • Bertotti, A. et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1, 508-523 (2011).
    • (2011) Cancer Discov. , vol.1 , pp. 508-523
    • Bertotti, A.1
  • 73
    • 84878862323 scopus 로고    scopus 로고
    • Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
    • Bardelli, A. et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3, 658-673 (2013).
    • (2013) Cancer Discov. , vol.3 , pp. 658-673
    • Bardelli, A.1
  • 74
    • 84932608425 scopus 로고    scopus 로고
    • Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer
    • Dienstmann, R. et al. Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer. Cancer Discov. 5, 598-609 (2015).
    • (2015) Cancer Discov. , vol.5 , pp. 598-609
    • Dienstmann, R.1
  • 75
    • 84963976837 scopus 로고    scopus 로고
    • Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial
    • Sartore-Bianchi, A. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 17, 738-746 (2016).
    • (2016) Lancet Oncol. , vol.17 , pp. 738-746
    • Sartore-Bianchi, A.1
  • 76
    • 84982814963 scopus 로고    scopus 로고
    • Intra-patient inter-metastatic genetic heterogeneity in colorectal cancer as a key determinant of survival after curative liver resection
    • Sveen, A. et al. Intra-patient inter-metastatic genetic heterogeneity in colorectal cancer as a key determinant of survival after curative liver resection. PLoS Genet. 12, e1006225 (2016).
    • (2016) PLoS Genet. , vol.12 , pp. e1006225
    • Sveen, A.1
  • 77
    • 84923952286 scopus 로고    scopus 로고
    • A Big Bang model of human colorectal tumor growth
    • Sottoriva, A. et al. A Big Bang model of human colorectal tumor growth. Nat. Genet. 47, 209-216 (2015).
    • (2015) Nat. Genet. , vol.47 , pp. 209-216
    • Sottoriva, A.1
  • 78
    • 84951810474 scopus 로고    scopus 로고
    • Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer
    • Kopetz, S. et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J. Clin. Oncol. 33, 4032-4038 (2015).
    • (2015) J. Clin. Oncol. , vol.33 , pp. 4032-4038
    • Kopetz, S.1
  • 79
    • 84905967636 scopus 로고    scopus 로고
    • Phase i expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations
    • Zimmer, L. et al. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. Clin. Cancer Res. 20, 4251-4261 (2014).
    • (2014) Clin. Cancer Res. , vol.20 , pp. 4251-4261
    • Zimmer, L.1
  • 80
    • 84968415547 scopus 로고    scopus 로고
    • Updated results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)
    • Van Cutsem, E. et al. Updated results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). Ann. Oncol. 26, iv119 (2015).
    • (2015) Ann. Oncol. , vol.26 , pp. iv119
    • Van Cutsem, E.1
  • 81
    • 84892150189 scopus 로고    scopus 로고
    • Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients
    • Guinney, J. et al. Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. Clin. Cancer Res. 20, 265-272 (2014).
    • (2014) Clin. Cancer Res. , vol.20 , pp. 265-272
    • Guinney, J.1
  • 82
    • 84874645608 scopus 로고    scopus 로고
    • A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction
    • Tian, S. et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut 62, 540-549 (2013).
    • (2013) Gut , vol.62 , pp. 540-549
    • Tian, S.1
  • 83
    • 84925324704 scopus 로고    scopus 로고
    • Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer
    • Van Cutsem, E. et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J. Clin. Oncol. 33, 692-700 (2015).
    • (2015) J. Clin. Oncol. , vol.33 , pp. 692-700
    • Van Cutsem, E.1
  • 84
    • 84883680951 scopus 로고    scopus 로고
    • Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
    • Douillard, J. Y. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369, 1023-1034 (2013).
    • (2013) N. Engl. J. Med. , vol.369 , pp. 1023-1034
    • Douillard, J.Y.1
  • 85
    • 84929141867 scopus 로고    scopus 로고
    • Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials
    • Sorich, M. J. et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann. Oncol. 26, 13-21 (2015).
    • (2015) Ann. Oncol. , vol.26 , pp. 13-21
    • Sorich, M.J.1
  • 86
    • 84873509424 scopus 로고    scopus 로고
    • Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: Implications for treatment of metastatic colorectal cancer
    • Dono, M. et al. Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer. Mol. Med. 18, 1519-1526 (2012).
    • (2012) Mol. Med. , vol.18 , pp. 1519-1526
    • Dono, M.1
  • 87
    • 84929463919 scopus 로고    scopus 로고
    • Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy
    • Laurent-Puig, P. et al. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin. Cancer Res. 21, 1087-1097 (2015).
    • (2015) Clin. Cancer Res. , vol.21 , pp. 1087-1097
    • Laurent-Puig, P.1
  • 88
    • 84941654132 scopus 로고    scopus 로고
    • Heterogeneity of driver genes and therapeutic implications in colorectal cancer
    • Dienstmann, R. & Cervantes, A. Heterogeneity of driver genes and therapeutic implications in colorectal cancer. Ann. Oncol. 26, 1523-1525 (2015).
    • (2015) Ann. Oncol. , vol.26 , pp. 1523-1525
    • Dienstmann, R.1    Cervantes, A.2
  • 89
    • 84939181687 scopus 로고    scopus 로고
    • HER2 activating mutations are targets for colorectal cancer treatment
    • Kavuri, S. M. et al. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov. 5, 832-841 (2015).
    • (2015) Cancer Discov. , vol.5 , pp. 832-841
    • Kavuri, S.M.1
  • 90
    • 77955277111 scopus 로고    scopus 로고
    • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis
    • De Roock, W. et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11, 753-762 (2010).
    • (2010) Lancet Oncol. , vol.11 , pp. 753-762
    • De Roock, W.1
  • 91
    • 84862987061 scopus 로고    scopus 로고
    • Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer
    • Weickhardt, A. J. et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J. Clin. Oncol. 30, 1505-1512 (2012).
    • (2012) J. Clin. Oncol. , vol.30 , pp. 1505-1512
    • Weickhardt, A.J.1
  • 92
    • 84939619336 scopus 로고    scopus 로고
    • Enhanced targeting of the EGFR network with MM-151, an oligoclonal anti- EGFR antibody therapeutic
    • Kearns, J. D. et al. Enhanced targeting of the EGFR network with MM-151, an oligoclonal anti- EGFR antibody therapeutic. Mol. Cancer Ther. 14, 1625-1636 (2015).
    • (2015) Mol. Cancer Ther. , vol.14 , pp. 1625-1636
    • Kearns, J.D.1
  • 93
    • 84856717005 scopus 로고    scopus 로고
    • Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
    • Montagut, C. et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat. Med. 18, 221-223 (2012).
    • (2012) Nat. Med. , vol.18 , pp. 221-223
    • Montagut, C.1
  • 94
    • 84941991989 scopus 로고    scopus 로고
    • Safety and pharmacokinetics/pharmacodynamics of the first-in-class dual action HER3/EGFR antibody MEHD7945A in locally advanced or metastatic epithelial tumors
    • Juric, D. et al. Safety and pharmacokinetics/pharmacodynamics of the first-in-class dual action HER3/EGFR antibody MEHD7945A in locally advanced or metastatic epithelial tumors. Clin. Cancer Res. 21, 2462-2470 (2015).
    • (2015) Clin. Cancer Res. , vol.21 , pp. 2462-2470
    • Juric, D.1
  • 95
    • 84955418383 scopus 로고    scopus 로고
    • A randomized phase II/III study of dalotuzumab in combination with cetuximab and irinotecan in chemorefractory, KRAS wild-type, metastatic colorectal cancer
    • Sclafani, F. et al. A randomized phase II/III study of dalotuzumab in combination with cetuximab and irinotecan in chemorefractory, KRAS wild-type, metastatic colorectal cancer. J. Natl Cancer Inst. 107, djv258 (2015).
    • (2015) J. Natl Cancer Inst. , vol.107 , pp. djv258
    • Sclafani, F.1
  • 96
    • 84905968151 scopus 로고    scopus 로고
    • Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer
    • Van Cutsem, E. et al. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin. Cancer Res. 20, 4240-4250 (2014).
    • (2014) Clin. Cancer Res. , vol.20 , pp. 4240-4250
    • Van Cutsem, E.1
  • 97
    • 85010845593 scopus 로고    scopus 로고
    • Phase II study of tivantinib (ARQ 197) in combination with cetuximab in EGFR inhibitor-resistant, MET-high, KRAS wild-type (KRASwt) metastatic colorectal cancer (mCRC)
    • Rimassa, L. et al. Phase II study of tivantinib (ARQ 197) in combination with cetuximab in EGFR inhibitor-resistant, MET-high, KRAS wild-type (KRASwt) metastatic colorectal cancer (mCRC). Ann. Oncol. 26, iv108-iv116 (2015).
    • (2015) Ann. Oncol. , vol.26 , pp. iv108-iv116
    • Rimassa, L.1
  • 98
    • 84887118578 scopus 로고    scopus 로고
    • Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab
    • Iida, M. et al. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia 15, 1196-1206 (2013).
    • (2013) Neoplasia , vol.15 , pp. 1196-1206
    • Iida, M.1
  • 99
    • 84908441752 scopus 로고    scopus 로고
    • TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells
    • Hobor, S. et al. TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. Clin. Cancer Res. 20, 6429-6438 (2014).
    • (2014) Clin. Cancer Res. , vol.20 , pp. 6429-6438
    • Hobor, S.1
  • 100
    • 84919964289 scopus 로고    scopus 로고
    • The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
    • Kawakami, H. et al. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget 5, 11847-11856 (2014).
    • (2014) Oncotarget , vol.5 , pp. 11847-11856
    • Kawakami, H.1
  • 101
    • 84896532797 scopus 로고    scopus 로고
    • MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors
    • Luraghi, P. et al. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res. 74, 1857-1869 (2014).
    • (2014) Cancer Res. , vol.74 , pp. 1857-1869
    • Luraghi, P.1
  • 102
    • 84942325212 scopus 로고    scopus 로고
    • Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
    • Misale, S. et al. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nat. Commun. 6, 8305 (2015).
    • (2015) Nat. Commun. , vol.6 , pp. 8305
    • Misale, S.1
  • 103
    • 84961063545 scopus 로고    scopus 로고
    • A phase i study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer
    • Deming, D. A. et al. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Invest. New Drugs 34, 168-175 (2015).
    • (2015) Invest. New Drugs , vol.34 , pp. 168-175
    • Deming, D.A.1
  • 104
    • 84930804509 scopus 로고    scopus 로고
    • Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
    • Brule, S. Y. et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur. J. Cancer 51, 1405-1414 (2015).
    • (2015) Eur. J. Cancer , vol.51 , pp. 1405-1414
    • Brule, S.Y.1
  • 105
    • 84983782183 scopus 로고    scopus 로고
    • Impact of primary tumor location on overall survival and progression-free survival in patients with metastatic colorectal cancer: Analysis of CALGB/SWOG 80405 (Alliance)
    • abstr. 3504
    • Venook, A. P. et al. Impact of primary tumor location on overall survival and progression-free survival in patients with metastatic colorectal cancer: analysis of CALGB/SWOG 80405 (Alliance). J. Clin. Oncol. 34, abstr. 3504 (2016).
    • (2016) J. Clin. Oncol. , vol.34
    • Venook, A.P.1
  • 106
    • 84985018675 scopus 로고    scopus 로고
    • Association of primary site and molecular features with progression-free survival and overall survival of metastatic colorectal cancer after anti-epidermal growth factor receptor therapy
    • abstr. 3506
    • Lee, M. S. et al. Association of primary site and molecular features with progression-free survival and overall survival of metastatic colorectal cancer after anti-epidermal growth factor receptor therapy. J. Clin. Oncol. 34, abstr. 3506 (2016).
    • (2016) J. Clin. Oncol. , vol.34
    • Lee, M.S.1
  • 107
    • 84922536963 scopus 로고    scopus 로고
    • Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
    • Missiaglia, E. et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann. Oncol. 25, 1995-2001 (2014).
    • (2014) Ann. Oncol. , vol.25 , pp. 1995-2001
    • Missiaglia, E.1
  • 108
    • 73349094741 scopus 로고    scopus 로고
    • Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    • Laurent-Puig, P. et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol. 27, 5924-5930 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , pp. 5924-5930
    • Laurent-Puig, P.1
  • 109
    • 84921766164 scopus 로고    scopus 로고
    • IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies
    • Zanella, E. R. et al. IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. Sci. Transl Med. 7, 272ra12 (2015).
    • (2015) Sci. Transl Med. , vol.7 , pp. 272ra12
    • Zanella, E.R.1
  • 110
    • 85011003019 scopus 로고    scopus 로고
    • Practical and robust identification of molecular subtypes in colorectal cancer by immunohistochemistry
    • Trinh, A. et al. Practical and robust identification of molecular subtypes in colorectal cancer by immunohistochemistry. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.ccr-16-0680 (2016).
    • (2016) Clin. Cancer Res.
    • Trinh, A.1
  • 111
    • 78651318026 scopus 로고    scopus 로고
    • Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (ErbituxTM) efficacy in KRAS wild-type tumor cells
    • Oliveras-Ferraros, C. et al. Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (ErbituxTM) efficacy in KRAS wild-type tumor cells. J. Cell. Biochem. 112, 10-29 (2011).
    • (2011) J. Cell. Biochem. , vol.112 , pp. 10-29
    • Oliveras-Ferraros, C.1
  • 112
    • 84922561479 scopus 로고    scopus 로고
    • Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: The randomised phase I/II POSEIDON trial
    • Elez, E. et al. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann. Oncol. 26, 132-140 (2015).
    • (2015) Ann. Oncol. , vol.26 , pp. 132-140
    • Elez, E.1
  • 113
    • 84939934190 scopus 로고    scopus 로고
    • Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer
    • Do, K. et al. Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer. Invest. New Drugs 33, 720-728 (2015).
    • (2015) Invest. New Drugs , vol.33 , pp. 720-728
    • Do, K.1
  • 114
    • 84881508779 scopus 로고    scopus 로고
    • Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer
    • Liu, Y. et al. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov. 3, 870-879 (2013).
    • (2013) Cancer Discov. , vol.3 , pp. 870-879
    • Liu, Y.1
  • 115
    • 84886787846 scopus 로고    scopus 로고
    • Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer
    • Kim, H. S. et al. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell 155, 552-566 (2013).
    • (2013) Cell , vol.155 , pp. 552-566
    • Kim, H.S.1
  • 116
    • 84938794719 scopus 로고    scopus 로고
    • Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities
    • Skoulidis, F. et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 5, 860-877 (2015).
    • (2015) Cancer Discov. , vol.5 , pp. 860-877
    • Skoulidis, F.1
  • 117
    • 84949679802 scopus 로고    scopus 로고
    • Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH
    • Yun, J. et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350, 1391-1396 (2015).
    • (2015) Science , vol.350 , pp. 1391-1396
    • Yun, J.1
  • 118
    • 84904645105 scopus 로고    scopus 로고
    • Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer
    • Gross, M. I. et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 13, 890-901 (2014).
    • (2014) Mol. Cancer Ther. , vol.13 , pp. 890-901
    • Gross, M.I.1
  • 119
    • 84949818415 scopus 로고    scopus 로고
    • Inhibition of de novo palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cell membranes inhibiting signaling pathways and reprogramming gene expression
    • Ventura, R. et al. Inhibition of de novo palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cell membranes, inhibiting signaling pathways, and reprogramming gene expression. EBioMedicine 2, 806-822 (2015).
    • (2015) EBioMedicine , vol.2 , pp. 806-822
    • Ventura, R.1
  • 120
    • 84864285794 scopus 로고    scopus 로고
    • Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
    • Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
    • (2012) Nature , vol.487 , pp. 500-504
    • Straussman, R.1
  • 121
    • 85010858470 scopus 로고    scopus 로고
    • Clinical outcome from oxaliplatin treatment in stage II/III colon cancer according to intrinsic subtypes: Secondary analysis of NSABP C-07/NRG oncology randomized clinical trial
    • Song, N. et al. Clinical outcome from oxaliplatin treatment in stage II/III colon cancer according to intrinsic subtypes: secondary analysis of NSABP C-07/NRG oncology randomized clinical trial. JAMA Oncol. 2, 1162-1169 (2016).
    • (2016) JAMA Oncol. , vol.2 , pp. 1162-1169
    • Song, N.1
  • 122
    • 84925818452 scopus 로고    scopus 로고
    • Stromal gene expression defines poor-prognosis subtypes in colorectal cancer
    • Calon, A. et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47, 320-329 (2015).
    • (2015) Nat. Genet. , vol.47 , pp. 320-329
    • Calon, A.1
  • 123
    • 85010884666 scopus 로고    scopus 로고
    • Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer
    • MoTriColor
    • MoTriColor. Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer. CORDIS http://cordis.europa.eu/project/rcn/193328-es.html (2015).
    • (2015) CORDIS
  • 124
    • 84922369531 scopus 로고    scopus 로고
    • Promotion of colorectal cancer invasion and metastasis through activation of NOTCH-DAB1-ABL-RHOGEF protein TRIO
    • Sonoshita, M. et al. Promotion of colorectal cancer invasion and metastasis through activation of NOTCH-DAB1-ABL-RHOGEF protein TRIO. Cancer Discov. 5, 198-211 (2015).
    • (2015) Cancer Discov. , vol.5 , pp. 198-211
    • Sonoshita, M.1
  • 125
    • 84892158897 scopus 로고    scopus 로고
    • AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer
    • Dunne, P. D. et al. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clin. Cancer Res. 20, 164-175 (2014).
    • (2014) Clin. Cancer Res. , vol.20 , pp. 164-175
    • Dunne, P.D.1
  • 126
    • 85031841084 scopus 로고    scopus 로고
    • Targeting the TGFb pathway with galunisertib, a TGFbRI SMI, promotes antitumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition
    • Schaer, D. et al. Targeting the TGFb pathway with galunisertib, a TGFbRI SMI, promotes antitumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. Cancer Immunol. Res. 4, A091 (2016).
    • (2016) Cancer Immunol. Res. , vol.4 , pp. A091
    • Schaer, D.1
  • 127
    • 84962319761 scopus 로고    scopus 로고
    • STAT3 signaling is required for optimal regression of large established tumors in mice treated with anti-OX40 and TGFβ receptor blockade
    • Triplett, T. A. et al. STAT3 signaling is required for optimal regression of large established tumors in mice treated with anti-OX40 and TGFβ receptor blockade. Cancer Immunol. Res. 3, 526-535 (2015).
    • (2015) Cancer Immunol. Res. , vol.3 , pp. 526-535
    • Triplett, T.A.1
  • 128
    • 84937511808 scopus 로고    scopus 로고
    • TGFβ inhibition prior to hypofractionated radiation enhances efficacy in preclinical models
    • Young, K. H. et al. TGFβ inhibition prior to hypofractionated radiation enhances efficacy in preclinical models. Cancer Immunol. Res. 2, 1011-1022 (2014).
    • (2014) Cancer Immunol. Res. , vol.2 , pp. 1011-1022
    • Young, K.H.1
  • 129
    • 84954053129 scopus 로고    scopus 로고
    • Targeting YAP-dependent MDSC infiltration impairs tumor progression
    • Wang, G. et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov. 6, 80-95 (2016).
    • (2016) Cancer Discov. , vol.6 , pp. 80-95
    • Wang, G.1
  • 130
    • 84959133719 scopus 로고    scopus 로고
    • Combination cancer immunotherapies tailored to the tumour microenvironment
    • Smyth, M. J., Ngiow, S. F., Ribas, A. & Teng, M. W. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat. Rev. Clin. Oncol. 13, 143-158 (2015).
    • (2015) Nat. Rev. Clin. Oncol. , vol.13 , pp. 143-158
    • Smyth, M.J.1    Ngiow, S.F.2    Ribas, A.3    Teng, M.W.4
  • 131
    • 84969545536 scopus 로고    scopus 로고
    • HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma
    • Zheng, H. et al. HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma. Clin. Cancer Res. 22, 4119-4132 (2016).
    • (2016) Clin. Cancer Res. , vol.22 , pp. 4119-4132
    • Zheng, H.1
  • 132
    • 75749147533 scopus 로고    scopus 로고
    • Immunogenic death of colon cancer cells treated with oxaliplatin
    • Tesniere, A. et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29, 482-491 (2010).
    • (2010) Oncogene , vol.29 , pp. 482-491
    • Tesniere, A.1
  • 133
    • 84902124970 scopus 로고    scopus 로고
    • Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
    • Motz, G. T. et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20, 607-615 (2014).
    • (2014) Nat. Med. , vol.20 , pp. 607-615
    • Motz, G.T.1
  • 134
    • 84960450202 scopus 로고    scopus 로고
    • MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade
    • Ebert, P. J. et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 44, 609-621 (2016).
    • (2016) Immunity , vol.44 , pp. 609-621
    • Ebert, P.J.1
  • 135
    • 84995336454 scopus 로고    scopus 로고
    • Clinical activity and safety of cobimetinib and atezolizumab in colorectal cancer
    • abstr. 3502
    • Bendell, J. C. et al. Clinical activity and safety of cobimetinib and atezolizumab in colorectal cancer. J. Clin. Oncol. 34, abstr. 3502 (2016).
    • (2016) J. Clin. Oncol. , vol.34
    • Bendell, J.C.1
  • 136
    • 84925273291 scopus 로고    scopus 로고
    • Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial
    • Perez, E. A. et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. J. Clin. Oncol. 33, 701-708 (2015).
    • (2015) J. Clin. Oncol. , vol.33 , pp. 701-708
    • Perez, E.A.1
  • 137
    • 84928585501 scopus 로고    scopus 로고
    • Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting precision cancer medicine to the test
    • Dienstmann, R., Rodon, J. & Tabernero, J. Optimal design of trials to demonstrate the utility of genomically-guided therapy: putting precision cancer medicine to the test. Mol. Oncol. 9, 940-950 (2015).
    • (2015) Mol. Oncol. , vol.9 , pp. 940-950
    • Dienstmann, R.1    Rodon, J.2    Tabernero, J.3
  • 138
    • 84859403854 scopus 로고    scopus 로고
    • Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial
    • Alberts, S. R. et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307, 1383-1393 (2012).
    • (2012) JAMA , vol.307 , pp. 1383-1393
    • Alberts, S.R.1
  • 139
    • 84903547973 scopus 로고    scopus 로고
    • Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): An open-label, randomised phase 3 trial
    • Taieb, J. et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol. 15, 862-873 (2014).
    • (2014) Lancet Oncol. , vol.15 , pp. 862-873
    • Taieb, J.1
  • 140
    • 84873328631 scopus 로고    scopus 로고
    • Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial
    • Allegra, C. J. et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J. Clin. Oncol. 31, 359-364 (2013).
    • (2013) J. Clin. Oncol. , vol.31 , pp. 359-364
    • Allegra, C.J.1
  • 141
    • 84870244259 scopus 로고    scopus 로고
    • Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): A phase 3 randomised controlled trial
    • de Gramont, A. et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 13, 1225-1233 (2012).
    • (2012) Lancet Oncol. , vol.13 , pp. 1225-1233
    • De Gramont, A.1
  • 142
    • 84951745408 scopus 로고    scopus 로고
    • Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer
    • Corcoran, R. B. et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J. Clin. Oncol. 33, 4023-4031 (2015).
    • (2015) J. Clin. Oncol. , vol.33 , pp. 4023-4031
    • Corcoran, R.B.1
  • 143
    • 84933040790 scopus 로고    scopus 로고
    • Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations
    • Ahronian, L. G. et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov. 5, 358-367 (2015).
    • (2015) Cancer Discov. , vol.5 , pp. 358-367
    • Ahronian, L.G.1
  • 144
    • 84982684991 scopus 로고    scopus 로고
    • Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer
    • Oddo, D. et al. Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer. Cancer Res. 76, 4504-4515 (2016).
    • (2016) Cancer Res. , vol.76 , pp. 4504-4515
    • Oddo, D.1
  • 145
    • 84861863158 scopus 로고    scopus 로고
    • EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
    • Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227-235 (2012).
    • (2012) Cancer Discov. , vol.2 , pp. 227-235
    • Corcoran, R.B.1
  • 146
    • 84863230465 scopus 로고    scopus 로고
    • Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
    • Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103 (2012).
    • (2012) Nature , vol.483 , pp. 100-103
    • Prahallad, A.1
  • 147
    • 85010892291 scopus 로고    scopus 로고
    • Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC)
    • abstr. 3544
    • Tabernero, J. et al. Phase 2 results: encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). J. Clin. Oncol. 34, abstr. 3544 (2016).
    • (2016) J. Clin. Oncol. , vol.34
    • Tabernero, J.1
  • 148
    • 10844274194 scopus 로고    scopus 로고
    • Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial
    • Ramanathan, R. K. et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest. 22, 858-865 (2004).
    • (2004) Cancer Invest. , vol.22 , pp. 858-865
    • Ramanathan, R.K.1
  • 149
    • 84928811801 scopus 로고    scopus 로고
    • The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
    • Medico, E. et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nat. Commun. 6, 7002 (2015).
    • (2015) Nat. Commun. , vol.6 , pp. 7002
    • Medico, E.1
  • 150
    • 84954071006 scopus 로고    scopus 로고
    • Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer
    • Sartore-Bianchi, A. et al. Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer. J. Natl Cancer Inst. 108, djv306 (2016).
    • (2016) J. Natl Cancer Inst. , vol.108 , pp. djv306
    • Sartore-Bianchi, A.1
  • 151
    • 84928974420 scopus 로고    scopus 로고
    • Prospective derivation of a living organoid biobank of colorectal cancer patients
    • van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933-945 (2015).
    • (2015) Cell , vol.161 , pp. 933-945
    • Van De Wetering, M.1
  • 152
    • 84938848181 scopus 로고    scopus 로고
    • Wnt addiction of genetically defined cancers reversed by PORCN inhibition
    • Madan, B. et al. Wnt addiction of genetically defined cancers reversed by PORCN inhibition. Oncogene 35, 2197-2207 (2015).
    • (2015) Oncogene , vol.35 , pp. 2197-2207
    • Madan, B.1
  • 153
    • 84989219878 scopus 로고    scopus 로고
    • Phase i study of WNT974, a first-in-class Porcupine inhibitor, in advanced solid tumors
    • abstr. C45
    • Janku, F. et al. Phase I study of WNT974, a first-in-class Porcupine inhibitor, in advanced solid tumors. Mol. Cancer Ther. 14, abstr. C45 (2015).
    • (2015) Mol. Cancer Ther. , vol.14
    • Janku, F.1
  • 154
    • 84953911698 scopus 로고    scopus 로고
    • Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function
    • Storm, E. E. et al. Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function. Nature 529, 97-100 (2015).
    • (2015) Nature , vol.529 , pp. 97-100
    • Storm, E.E.1
  • 155
    • 84932628341 scopus 로고    scopus 로고
    • PD-1 blockade in tumors with mismatch-repair deficiency
    • Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520 (2015).
    • (2015) N. Engl. J. Med. , vol.372 , pp. 2509-2520
    • Le, D.T.1
  • 156
    • 84982314960 scopus 로고    scopus 로고
    • Nivolumab ? Ipilimumab in treatment of patients with metastatic colorectal cancer with and without high microsatellite instability: CheckMate-142 interim results
    • abstr. 3501
    • Overman, M. J. et al. Nivolumab ? ipilimumab in treatment of patients with metastatic colorectal cancer with and without high microsatellite instability: CheckMate-142 interim results. J. Clin. Oncol. 34, abstr. 3501 (2016).
    • (2016) J. Clin. Oncol. , vol.34
    • Overman, M.J.1
  • 157
    • 84963553379 scopus 로고    scopus 로고
    • Genomic correlates of immune-cell infiltrates in colorectal cancer
    • Giannakis, M. et al. Genomic correlates of immune-cell infiltrates in colorectal cancer. Cell Rep. 15, 857-865 (2016).
    • (2016) Cell Rep. , vol.15 , pp. 857-865
    • Giannakis, M.1
  • 158
    • 84941630950 scopus 로고    scopus 로고
    • Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
    • Tie, J. K. et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann. Oncol. 26, 1715-1722 (2015).
    • (2015) Ann. Oncol. , vol.26 , pp. 1715-1722
    • Tie, J.K.1
  • 159
    • 84978062740 scopus 로고    scopus 로고
    • Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
    • Tie, J. K. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl Med. 8, 346ra92 (2016).
    • (2016) Sci. Transl Med. , vol.8 , pp. 346ra92
    • Tie, J.K.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.